home / stock / vtgn / vtgn news

VTGN News and Press, VistaGen Therapeutics Inc. From 09/08/21

Stock Information
Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com
Menu
VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...
VTGN - VistaGen Therapeutics to Participate in Baird's 2021 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central...
VTGN - InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Plans Q1 Financials, Corporate Update

VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...

VTGN - VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q1 2022 Results - Earnings Call Transcript

VistaGen Therapeutics, Inc. (VTGN) Q1 2022 Earnings Conference Call August 12, 2021 05:00 PM ET Company Participants Mark Flather - Vice President, Investor Relations Shawn Singh - Chief Executive Officer Jerry Dotson - Chief Financial Officer Mark Smith - Chief Medical Officer Conference Cal...

VTGN - VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update

PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan Additional potential NDA-enabling clinical studies expected to initiate in 2021 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021...
VTGN - InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Plans to Release Q1 Financials, Host Earnings Call

VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...

VTGN - VistaGen Therapeutics to Report Fiscal Year 2022 First Quarter Financial Results and Host Conference Call and Webcast on August 12, 2021

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and oth...

VTGN - InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Canaccord Genuity 41st Annual Growth Conference

VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...
VTGN - VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central ...

VTGN - InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Strategic Board Appointment

VistaGen (NASDAQ: VTGN) , a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Maggie FitzPatr...

VTGN - VistaGen Therapeutics adds Maggie FitzPatrick to its board of directors

VistaGen Therapeutics (VTGN) announces the appointment of Maggie FitzPatrick to the company's board of directors.FitzPatrick replaces Brian Underdown who recently retired from the board.Recently, she served as a member of the Exelon Corporation executive committee. ...
Previous 10 Next 10